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Abstract
Great strides have been made in understanding the epidemiology of EoE over the past two
decades. Initial research focused on case description and characterization of the burden of disease.
Research is now shifting to risk factor ascertainment, resulting in new and intriguing etiologic
hypotheses. This paper will review the current knowledge related to the epidemiology of EoE.
Demographic features and natural history will be described, data summarizing the prevalence and
incidence of EoE throughout the world will be highlighted, and risk factors for EoE will be
discussed. EoE can occur at any age, there is a male predominance, it is more common in Whites,
and there is a strong association with atopic diseases. EoE is chronic, relapses are frequent, and
persistent inflammation increases the risk of fibrostenotic complications. The prevalence is
currently estimated at 0.5–1 in 1000, and EoE is now the most common cause of food impaction.
EoE can be seen in 2–7% of patients undergoing endoscopy for any reason, and 12–23%
undergoing endoscopy for dysphagia. The incidence of EoE is approximately 1/10,000 new cases
per year, and the rise in incidence is outpacing increases in recognition and endoscopy volume.
The reasons for this evolving epidemiology are not yet fully delineated, but possibilities include
changes in food allergens, increasing aeroallergens and other environmental factors, the decrease
of H. pyloriand early life exposures.
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Introduction
Epidemiology is the study of patterns and causes of diseases in defined populations. It uses
observational study designs, such as case-control or cohort studies, to make inferences about
etiologies and risk factors for diseases. These results generate hypotheses that can
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subsequently be tested in experimental study designs, such as clinic trials. Over the past two
decades, there have been great strides made in understanding the epidemiology of
eosinophilic esophagitis (EoE). Case reports and case series provided initial descriptions of
clinical characteristics of patients with EoE,1–4 and then as larger cohorts were reported and
natural history data accumulated,5–11 formal disease definitions and guidelines were put
forth.12–14 Epidemiologic techniques have been used to estimate the incidence and
prevalence of EoE at the single center, regional, and national levels to provide an
understanding of trends in the number of cases as well as the burden of disease attributable
to EoE.15–22 The clear result of these studies is that EoE is rapidly increasing both in
incidence and in prevalence. Investigations have also begun to determine potential etiologic
factors that might explain this evolving epidemiology. This paper will review the current
knowledge base related to the epidemiology of EoE. In particular, demographic features and
natural history will be described, data summarizing the prevalence and incidence of EoE
throughout the world will be highlighted, and risk factors for EoE will be discussed.
Demographic features
EoE has been reported throughout the lifespan, from infancy to almost 100 years of
age.10,13,23 However, the majority of cases are in children, adolescents, and adults under the
age of 50.10,13,22–24 There is a consistent gender discrepancy, with males affected three to
four times more commonly than females, and EoE is also more frequently reported in
Whites compared with other races/ethnicities.11,13,19,22,24–27 The reason for the male
predominance is not known, and as more data accrues from larger centers with more diverse
patient populations, increasing numbers of racial minorities have been identified with
EoE.28–31 While the majority of clinical, endoscopic, and histologic features are shared by
EoE patients of different races, some data suggest that African-Americans with EoE may be
diagnosed at earlier ages and are less likely to have typical endoscopic findings of EoE.28,31
EoE is also strongly associated with atopic disease and can run in families; both of these
topics, as well as the clinical features and differences in the presentation between adults and
children, are addressed in detail in other articles in this issue.
Natural History
EoE is considered a chronic disease.12–14 Data from the placebo arms of randomized clinical
trials32–38 and prospective and retrospective cohort studies5–7,10,11,39–41 show that EoE does
not tend to spontaneously resolve or “burn-out”. Specifically, the endoscopic signs and
esophageal eosinophilia persist in the absence of treatment. Moreover, if treatment is
stopped, symptoms, endoscopic signs, and esophageal eosinophilia recur in the vast majority
of patients over a period of several months.8,41–45 There are as of yet no published reports of
EoE transforming into hypereosinophilic syndrome, extending to involve other areas of the
GI tract, or causing a malignancy.6,7,10,11,40
Recent data have supported the concept that EoE may progress from an inflammatory-
predominant phenotype (primarily seen in children) to a fibrosis-predominant one (seen in
adults).13,46–48 These data help to explain the clinical differences between adults and
children,11,39,49,50 and are consistent with basic science work showing that esophageal
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remodelling and deposition of fibrosis are key pathogenic features of EoE.51,52 The
hypothesis is that in children, eosinophilic inflammation in the esophagus manifests with
white plaques or exudates, decreased vascularity or mucosa edema, and linear furrows, but
without esophageal rings or strictures, and causes symptoms such as pain, heartburn, and
failure to thrive. With ongoing inflammation, however, subepithelial collagen is deposited,
esophageal rings, narrowing, and strictures develop, and symptoms become dysphagia
predominant.
A retrospective cohort study of patients in Switzerland explored this issue by assessing
diagnostic delay – how long patients experienced symptoms prior to the EoE diagnosis and
before any treatment – as a proxy for ongoing inflammation.53 There was a very strong
association between increasing diagnostic delay and the prevalence of strictures at diagnosis.
For example, only 17% of those with less than 2 years of symptoms prior to diagnosis had
strictures compared with 71% with more than 20 years of symptoms. They calculated that
for every increased decade of untreated EoE, there was a doubling of odds of having an
esophageal stricture. Another study assessed the same issue by examining endoscopically-
defined phenotypes of EoE and noted nearly identical results, with the odds of having a
fibrostenotic EoE phenotype doubling with each increasing decade of age.48 These natural
history data provide important information for patients, show long term consequences of
EoE, and support the need for treatment of this condition.
Prevalence
The prevalence of a condition is defined by how many total cases exist during a given time
frame in a specified location, and is a useful measure of the burden of that disease. EoE has
been described in many places throughout the world including North America, Europe,
South America, Australia, Asia, and the Middle East, but the prevalence appears to be
highest in the U.S., Western Europe, and Australia as compared with Japan or
China.17–22,54–62 As of yet, there are no reported EoE cohorts in sub-Saharan Africa or
India.
The prevalence of EoE depends on the population that is studied, the definition of EoE that
was used (and whether the study was conducted before the recognition of proton pump
inhibitor-responsive esophageal eosinophilia [PPI-REE]),13,14 and the study methodology
(prospective vs retrospective), and this contributes to variation in the range of prevalence
estimates (Tables 1 and 2). While the majority of prevalence estimates are derived from
single-centers with defined catchment areas,15,16,18,20,58,59,63,64 there are some studies that
have used either population-based techniques or national databases to attempt to generate
more accurate or generalizable estimates.17,21,22,65–67 Because EoE is chronic and non-fatal,
studies universally report an increasing prevalence of EoE regardless of the geographic
location.54,68
Prevalence of EoE in the general population
How common is EoE? In reviewing data assessing the prevalence of EoE in general
populations (Table 1), a reasonable answer is 0.5–1 cases/1000 persons. The majority of
estimates in the U.S. range from 40–90 cases/100,000 persons.15,18,19,22,63,65 The largest
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study in the U.S. examined administrative health claims data and found the prevalence to be
57/100,000, or approximately 152,000 cases, with a range from 39–153/100,000 (106,000–
411,000 cases), based on the case definition that was used.22,69 These are consistent with the
most recent estimates from Australia (89/100,000),58 Switzerland (43/100,000),20 Spain
(45/100,000),59 and Canada (34/100,000).67 Additionally, these prevalence estimates are of
the same order of magnitude of pediatric Crohn’s disease and ulcerative colitis, and are
beginning to approach the prevalence of IBD overall,70 a remarkable observation given that
EoE was essentially unknown two decades ago.
Several studies, however, provide estimates that are outside of this range. In Northern
Sweden, data from a population-based study assessing the prevalence of Barrett’s esophagus
was reanalyzed and found a prevalence of 400/100,000 for EoE.17 These patients were
largely asymptomatic and while they had esophageal eosinophilia, may not have met current
diagnostic criteria for EoE.13,14 A study in the U.S. military found a prevalence of
10/100,000, but this might have been an underestimate due to the specialized population
assessed or to low sensitivity of the administrative code for EoE.66,69 Studies from the
Netherlands and the southern region of Denmark have also reported lower prevalences of
EoE.21,64 It is unknown if these results are due to practice patterns in those countries or a
true difference in the prevalence of disease.
Prevalence of EoE in patients undergoing endoscopy
While these prior studies assessed the overall prevalence of EoE, depending on the specific
patient population seen in health care settings the prevalence may be orders of magnitude
higher (Table 2). For example, a prospective study which collected esophageal biopsies on
consecutive patients undergoing upper endoscopy for any indication found that 6.5% of
patients were diagnosed with EoE.26 Other studies with a similar design found comparable
rates, from 2.4% to 6.6%.71,72 Given that there are approximately 6.9 million upper
endoscopies performed annually in the U.S.,73 endoscopists should expect to commonly
encounter EoE in the procedure suite.
EoE is even more common in patients undergoing upper endoscopy for symptoms of
dysphagia. In three prospectively studies conducted in this focused patient population, the
prevalence of EoE ranged from 12–22%.25,74,75 Not every patient in these studies with a
finding of esophageal eosinophilia, however, would meet current diagnostic guidelines with
exclusion of PPI-REE, because patients were enrolled prior to the recognition of this
phenomenon. A recent study conducted in an esophageal referral center reported an EoE
prevalence of 23% for patients undergoing endoscopy for dysphagia, after excluding those
patients with PPI-REE.76 In that study, esophageal eosinophilia itself was seen in 40% of
those undergoing upper endoscopy for dysphagia, before a PPI trial was conducted. Given
that approximately 20% of all upper endoscopies performed are for an indication of
dysphagia,73 EoE must be highly suspected in this population.
In the most extreme form of dysphagia, esophageal food bolus impaction requiring a visit to
an emergency department and urgent endoscopy, EoE is now the most frequent condition
identified. In this setting, between 46–63% of patients with food impaction will have
EoE.77–80 These data, however, are somewhat limited because less than half of patients with
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food or foreign body impactions will have esophageal biopsies to evaluate for esophageal
eosinophilia,78,80 so EoE in this setting may still be underdiagnosed. If patients have a bolus
impaction and no biopsies are obtained, it is reasonable to perform a follow-up procedure to
identify the underlying etiology.
The prevalence of EoE in patients undergoing endoscopy for other upper GI symptoms has
also been described. For patients with heartburn-predominant symptom who don’t respond
clinically to PPI therapy (PPI-refractory reflux), EoE has been identified as the cause
1%-8% of the time.26,42,61,76,81–84 In adults with non-cardiac chest pain, one study found
that EoE was the etiology in 6%.85 In children undergoing upper endoscopy for abdominal
pain, the frequency of EoE was 4%,86 and in children undergoing multispecialty evaluation
for refractory aerodigestive symptoms, it was also 4%.87
While these epidemiologic data have utility for understanding how common EoE is, building
a differential diagnosis for patients undergoing endoscopy, and measuring the burden of
disease attributable to EoE, they also imply a practical point. Because EoE is common in
patients undergoing endoscopic procedures, practitioners should strongly consider the
diagnosis and obtain esophageal biopsies to evaluate for it. Currently guidelines recommend
obtaining biopsies for all patients presenting with dysphagia, regardless of the endoscopic
appearance.12–14 There is also a recent analysis that suggests if the clinical probability of
EoE is at least 8–10%, obtaining biopsies in patients with PPI-refractory reflux is also cost-
effective.88
Incidence
The incidence of a condition is how many new cases occur during a given time frame in a
specified location, and is a measure of the number of people newly affected by a disease.
The incidence of a condition can be low (a small number of new cases), but the prevalence
can be relatively high if the condition is chronic and does not impact longevity.
Additionally, the incidence of a condition can be roughly equivalent to the prevalence for a
condition that is either short-lived or highly morbid.
In order to study the incidence of a condition, it is necessary not only to detect all new
(incident) cases, but to ensure that existing (prevalent) cases are not falsely counted as new
cases. In EoE, this has been accomplished primarily at referral centers in regions where the
patient population and catchment area is well defined,15,19,20,59,64 but there are some
emerging regional and national data as well.21,67 The majority of the reports estimate the
incidence of EoE from 6–13 cases/100,000 persons (Table 3). The two studies that report
lower incidence rates, from the Netherlands and the southern Denmark, were the same ones
that reported lower prevalences rates.21,64
Increasing incidence and risk factors
Studies are consistent in showing that the incidence of EoE has been rising rapidly. In a
report from Hamilton County, Ohio, the incidence of EoE was noted to increase from 9 to
12.8/100,000 over a three year period.15 In a report from Olmstead County, Minnesota, no
EoE cases were seen before 1990, but in the incidence rose from 0.35 to 9.5/100,000 over a
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15 year period.19 Similar increases have been reported in Switzerland (1.2 to 7.4/100,000
over a 20 year period)20 and in the Netherlands (0.01 to 1.3/100,000 over 14 years).21 This
increasing incidence has also been reflected in temporal trends in the relative prevalence of
dysphagia etiologies, with EoE becoming a more frequent cause of dysphagia over time.89
Why is eosinophilic esophagitis increasing?
While these marked changes in EoE incidence account for its increasing prevalence, they
also beg the question of why is the incidence itself increasing? While the answer is not
known, there are a number of hypothesis.90 One explanation is simply that EoE is increasing
because of increasing recognition; the condition was always there but given the research and
clinical interest in the condition, practitioners are more aware of EoE, have a higher degree
of suspicion when performing endoscopy, take more esophageal biopsies, and are therefore
more likely to make the diagnosis. The exponential increase in the number of publications
related to EoE is a testament to the increased interest in EoE (from 0–1 publication per year
prior to 2000, to >200 publications in 2013). Some data that support this theory show that
the increase in incidence rates relatively closely matches the increase in endoscopy volume
or biopsy rates.67,91 However, there are other studies where biopsy rates do increase 2–3
times over the study period, but the incidence of EoE outpaces that increase by several fold,
indicating that increased recognition is not the only explanation.11,19,89,92 Additionally, in
studies where archived pathology samples have been retrieved and reanalyzed, cases of
probable EoE identified in the early 1980s and 1990s occur at lower rates that what is
currently being observed.93,94
There are other epidemiologic clues that provide insight. Recent data suggest that the
prevalence of EoE steadily increases as age increases, peaks in the 35–45 age range, and
then decreases (Figure 1).22 This is a counterintuitive observation for a chronic and non-fatal
disease (where prevalence would be expected to continue to increase as age increases), and
suggests a possible cohort effect. It is interesting to speculate whether something might have
changed in the environment 40–50 years ago that began to affect children born after that
time, but did not affect older individuals. In contrast, genetic changes would not be expected
to impact a new disease over a relatively short time frame. This time frame is also consistent
with decades-long symptom duration prior to EoE diagnosis in some older patients with
EoE.23,48,90,95
Allergen and hygiene hypotheses
There are a number of etiologic risk factors that have either been identified or hypothesized
to contribute to the increase of EoE (Box 1). One possibility relates to EoE as an allergic
disease (see also the article on allergic mechanisms in this issue of Clinics). All allergic
diseases, including asthma, atopic dermatis, allergic rhinitis, and food allergies, have been
increasing in recent decades.96 One global explanation for this is the hygiene hypothesis,
which holds that because the environment in developed counties has become much more
sterile, human immune systems are exposed to smaller variety of antigens, and tolerance is
less likely to develop.96 Thus, EoE as an allergen/immune-mediated disease would be rising
in parallel with other allergic diseases.
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Related to the hygiene hypothesis are theories that changing environmental factors are
contributing to the rise in EoE. One factor is aeroallergens. There have been clear links in
humans between pollen and other aeroallergen exposure either triggering EoE or correlating
with EoE disease activity.97–99 Additionally, many studies have shown a link between the
season of the year and EoE diagnosis, with EoE more commonly being diagnosed in
summer or fall, times of potentially higher aeroallergen activity.11,19,100,101 Other
environmental exposures such as air pollution or industrial exposures, have yet to be
formally assessed.
Geographic risk factors have also been reported. Several studies have utilized a large
nationwide pathology database containing hundreds of thousands of patients undergoing
endoscopy with esophageal biopsy, and representing more than 14,000 cases of esophageal
eosinophilia and EoE.102,103 Prevalence of esophageal eosinophilia was noted to vary by
climate zone, with cases more commonly noted in arid and cold weather climates.102 This
was an interesting finding because the climate zone classification used is closely linked to
types of vegetation, again raising the question of allergen exposure, and also because other
autoimmune and allergic diseases have geographic variation with a north-south gradient. A
related study showed that esophageal eosinophilia appeared to be more common in rural
areas with low population density.103 While this may be counterintuitive (some allergic
diseases such as asthma and atopic dermatitis are felt to be more common in urban areas),
there are other studies on EoE that support this as well.65,104 This raises the question of
whether vegetation or environmental exposures more likely to be found in rural areas are
risk factors for EoE, but additional research is required to explore these possibilities.
Food allergens can also be considered environmental exposures. It is well-established that
foods can trigger EoE and that allergen-free elemental formula or elimination of certain food
allergens from the diet can result in clinical, endoscopic, and histologic remission (see also
the article on dietary therapy of EoE in this issue of Clinics).4,5,45,105,106 However, it is less
clear why foods that have been tolerated for much of human history are now allergic triggers
in EoE. Whether this is because of recent changes in agricultural practices, decreased variety
of foods, genetic modification of crops, pesticides, antibiotic or hormone use in livestock, or
other factors such as packaging and transport of foods remains to be determined.
Helicobacter pylori hypothesis
When thinking about reasons that EoE may be increasing, it is possible that something being
removed from the environment could also play a role. Helicobacter pylori is one such factor.
Since its formal characterization in the early 1980s and subsequent association with peptic
ulcer disease and gastric cancer, the prevalence of H. pylori has markedly decreased in the
U.S. with ongoing treatment of this pathogen.107 In a study examining more than 165,000
paired esophageal and gastric biopsy samples, there was a strong inverse relationship
between H. pylori and esophageal eosinophilia; those who were more likely to have
esophageal eosinophilia or EoE were less likely to have H. pylori.108 This relationship has
also been noted in two smaller studies in EoE,17,109 and is consistent with the observation
that H. pylori is inversely associated with other atopic disorders such as asthma and
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eczema.110 The mechanism by which H. pylori may be protective of EoE is not known, but
it has been hypothesized that the infection polarizes the immune system towards a Th1
response, and the lack of infection might allow a Th2 response, less tolerance, and increased
atopy.108
Proton pump inhibitor hypothesis
Another potential ecological association to explain the increase in EoE is the parallel
increase in use of PPI medications over the past three decades. This increase in use has also
been noted in infants as a treatment for reflux and colic, which represents a major change in
practice during a time when the immune system is developing.111 While there is no direct
evidence that PPI use has caused EoE in an individual patient, there are some intriguing
mechanistic reasons that this could be a concern, especially given the multitude of effects
that PPI have outside of their antisecretory action.112,113 Specifically, PPIs can increase
upper GI tract permeability, potentially creating a new route of antigen exposure, and their
use has also been associated with the development of new food-specific IgE
antibodies.112,114–116 However, these data are balanced by two important points. First, many
patients who are diagnosed with EoE have never taken a PPI previously. Second, convincing
data show that PPIs have anti-inflammatory/anti-eosinophil effects both in vitro117 and in
vivowhere at least 30–40% of subjects with esophageal eosinophilia have symptomatic and
histologic resolution after a PPI trial.76,118,119 Because of this, a PPI trial is now a required
part of the EoE diagnostic algorithm.12–14 Therefore, before PPIs can be considered to be a
cause of EoE, direct evidence will be required.
Early life exposure hypotheses
A new area of investigation has started to examine early life exposures that might predispose
to development of EoE. It has been noted that antibiotic exposure in early life increases the
odds of developing other allergic diseases such as asthma or atopic dermatitis and
inflammatory bowel disease, especially Crohn’s disease.120–122 There are recent pilot data
suggesting the same may be true in EoE, where exposures during the first year of life were
assessed and the subsequent odds of pediatric EoE determined.123 In this study, infants who
received antibiotics were markedly more likely to have EoE than controls who did not, and
there was also a trend for increased EoE in infants delivered by cesarian section, those who
were born prematurely, and those who had non-exclusive breastfeeding. All of these factors
could theoretically impact the early life microbiome, perturbations of which have been
hypothesized to be a determinant of atopic disease.124 Novel research techniques in EoE
have begun to characterize to esophageal microbiome, but this has yet to be fully explored
as a risk factor for EoE.125
Other hypotheses
A final set of risk factors for EoE that have been recently identified are connective tissue
and autoimmune disorders. A report in a large cohort of EoE patients found a subset with
coexisting diseases such as Ehlers-Danlos, Marfan, and Loeys-Dietz syndromes, in which
EoE was significantly elevated compared to expected rates in the general population.126
Moreover, this association suggested potential genetic links that could be used to learn more
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about the pathogenesis of EoE. In a preliminary study using administrative data, a similar
relationship between EoE and connective tissue disorders were noted, and there was also a
relationship with autoimmune diseases.127
Summary
The epidemiology of EoE has become increasingly well understood over the past decade.
The disease is well characterized clinically, and those features have informed diagnostic
guidelines. EoE can affect patients of any age, but there is a male predominance, it is more
common in Whites, and there is a strong association with atopic diseases. EoE is chronic,
relapses are frequent with cessation of treatment, and new data suggest that unopposed
inflammation and persistent symptoms with diagnostic delay increases the risk of
fibrostenotic complications. The prevalence of EoE is rising substantially, and it is now the
most common cause of food impaction in patients presenting to the emergency department,
and is frequently encountered in the endoscopy suite. Approximately 0.5–1 in 1000 people
are estimated to have EoE, a prevalence that is beginning to approach that of inflammatory
bowel disease. Incidence estimates suggest that there are 1/10,000 new cases per year, and
the rise in incidence is outpacing the increasing in recognition and endoscopy volume. The
reasons for this evolving epidemiology are not yet fully delineated, but possibilities include
changes in food allergens, increasing aeroallergens and other environmental factors, the
decrease of H. pyloriand early life exposures that may affect the microbiome. The study of
the epidemiology of EoE has now shifted from case description to risk factor ascertainment,
and new etiologic hypotheses have been raised that present exciting avenues for future
epidemiologic and pathogenic research in this condition, with the ultimate goal of
preventing the occurrence of EoE.
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• EoE affects patients of all ages, is more commonly seen in males and Whites,
and is strongly associated with atopy.
• EoE is chronic, relapses are frequent after treatment is stopped, and diagnostic
delay with persistent inflammation increases the risk of esophageal strictures
and fibrostenotic complications.
• The prevalence of EoE is 0.5–1 cases/1000 persons.
• The incidence of EoE is approximately 10 cases/10,000 persons per year.
• Elucidating the reasons for the rapid rise in incidence and prevalence of EoE is
an active area of research, and possibilities include changes food allergens and
aeroallergens, other environmental factors, the decrease of H. pyloriand early
life exposures.
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Prevalence of EoE (cases per 100,000) in the United States as stratified by sex and by 5 year
increments of age, in a study of an administrative health claims data. From Dellon ES,
Jensen ET, Martin CF, Shaheen NJ, Kappelman MD. Prevalence of Eosinophilic
Esophagitis in the United States. Clin Gastroenterol Hepatol 2013; with permission.
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Population-based estimates of the prevalence of EoE
Author Location Population Time frame Prevalence
(per 100,000)
Noel; Buckmeier Hamilton County, OH Pediatric 2000–2003; 2000–2006 43.0; 90.7
Cherian Perth, Australia Pediatric 1995, 1999, 2004 89.0
Straumann; Hruz Olten County, Switzerland Adult 1989–2004; 1989–2009 23.0 42.8
Ronkainen Northern Sweden Adult 1998–2001 400
Prasad Olmstead County, MN Adult and pediatric 1976–2005 55.0
Gill Huntington region, WV Pediatric 1995–2004 73.0
Dalby Southern Denmark Pediatric 2005–2007 2.3
Spergel United States Adult and pediatric 2010 52.2
Ally United States (military) Adult and pediatric 2009 9.7
van Rhijn Netherlands Adult and pediatric 1996–2010 4.1
Syed Calgary, Canada Adult and pediatric 2004–2008 33.7
Arias Castilla-La Manch region, Spain Adult and pediatric 2005–2011 44.6
Dellon United States Adult and pediatric 2009–2011 56.7
Data from Refs 15–22,58,59,63–67.
























Prevalence of EoE in selected patient populations undergoing endoscopy
Author Population Time frame Prevalence
(per 100)
Patients undergoing endoscopy for any reason
Veerappan Adults 2007 6.5
Joo Adults 2009 6.6
Sealock Adults (VA population) n/a 2.4
Patients undergoing endoscopy for dysphagia
Prasad Adults 2005–2006 15
Mackenzie Adults 2005–2007 12
Ricker Adults (non-obstructive dysphagia only) 2007–2009 22
Dellon Adults 2009–2011 23
Patients undergoing endoscopy for food bolus impaction
Desai Adults 2000–2003 55
Kerlin Adults n/a 50
Sperry Adults and pediatric 2002–2009 46
Hurtado Pediatric 2005–2009 63
Patients undergoing endoscopy for refractory reflux
Liacouras Pediatric 1993–1995 3
Rodrigro Adult 2002–2005 0.2
Veerappan Adult 2007 8
Sa Adult 2006–2008 1
Poh Adult n/a 1
Foroutan Adult 2006 8
Garcia-Campean Adult 2007–2009 4
Dellon Adult 2009–2011 2
Patients undergoing endoscopy for non-cardiac chest pain
Achem Adult 2006–2007 6
Patients undergoing endoscopy for abdominal pain
Thakkar Pediatric 2007–2010 4
Patients with refractory aerodigestive symptoms
Hill Pediatric 2003–2013 4
Data from Refs 25,26,41,42,61,71,72,74–87.
























Population-based estimates of the incidence of EoE*
Author Location Population Time frame Incidence
(per 100,000)
Noel Hamilton County, OH Pediatric 2003 12.8
Hruz Olten County, Switzerland Adult 2007–2009 7.4
Prasad Olmstead County, MN Adult and pediatric 2001–2005 9.5
Dalby Southern Denmark Pediatric 2005–2007 1.6
van Rhijn Netherlands Adult and pediatric 2010 1.3
Syed Calgary, Canada Adult and pediatric 2004–2008 11
Arias Castilla-La Manch region, Spain Adult and pediatric 2005–2011 6.4
*
The estimated incidence of the most recent time point in each study is presented Data from Refs 15,19–21,59,64,67.
























Potential etiologic risk factors for EoE
• Aeroallergens
• Food allergens
• Helicobacter pylori (protective)
• Proton pump inhibitors
• Cold or arid climates
• Population density (urban vs rural locations)
• Early life factors (antibiotic use; cesarian section)
• Connective tissue disorders
Data from Refs 4,45,65,97–100,102–105,108,109,112,123,126.
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